Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

34.93
+0.06000.17%
Post-market: 34.930.00000.00%19:30 EDT
Volume:1.96M
Turnover:68.26M
Market Cap:4.12B
PE:12.63
High:35.30
Open:34.87
Low:34.33
Close:34.87
52wk High:42.81
52wk Low:22.22
Shares:118.00M
Float Shares:116.45M
Volume Ratio:1.05
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-19.82
PE(LYR):21.30

Loading ...

Company Profile

Company Name:
INDIVIOR PLC
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
833
Office Location:
10710 Midlothian Turnpike,Suite 125,North Chesterfield,Virginia,United States
Zip Code:
23235
Fax:
- -
Introduction:
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Directors

Name
Position
Joe Ciaffoni
Chief Executive Officer and Executive Director
David Wheadon
Chair of the Board and Director
Barbara Ryan
Director
Daniel Ninivaggi
Director
Juliet Thompson
Director
Keith Humphreys
Director
Mark Stejbach
Director
Tony Kingsley
Director

Shareholders

Name
Position
Joe Ciaffoni
Chief Executive Officer and Executive Director
Ryan Preblick
Chief Financial Officer
Christian Heidbreder
Chief Scientific Officer
Jeff Burris
Chief Legal Officer
Pat Barry
Chief Commercial Officer
Woodrow Anderson
Chief Accounting Officer